HPV-FASTER: broadening the scope for prevention of HPV-related cancer

[1]  M. Poljak,et al.  Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  S. Franceschi,et al.  European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination , 2015, Papillomavirus Research.

[3]  Kate Soldan,et al.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis , 2015, BDJ.

[4]  J. Berkhof,et al.  Triaging HPV‐positive women with normal cytology by p16/Ki‐67 dual‐stained cytology testing: Baseline and longitudinal data , 2015, International Journal of Cancer.

[5]  Haifeng Xu,et al.  Value of Quantitative and Qualitative Analyses of Circulating Cell-Free DNA as Diagnostic Tools for Hepatocellular Carcinoma , 2015, Medicine.

[6]  J. Dillner,et al.  Organization and quality of HPV vaccination programs in Europe. , 2015, Vaccine.

[7]  A. Dempsey,et al.  Acceptability of human papillomavirus vaccines among women older than 26 years. , 2015, Vaccine.

[8]  E. Unger,et al.  Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. , 2015, Vaccine.

[9]  M. Lehtinen,et al.  Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. , 2015, Vaccine.

[10]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[11]  P. Lopalco,et al.  Safety of human papillomavirus vaccines: a review , 2015, Expert opinion on drug safety.

[12]  E. J. Mayeaux,et al.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. , 2015, Gynecologic oncology.

[13]  T. Agorastos,et al.  Distinct demographic factors influence the acceptance of vaccination against HPV , 2015, Archives of Gynecology and Obstetrics.

[14]  M. Jit,et al.  Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model , 2015, BMJ : British Medical Journal.

[15]  Jack T Stapleton,et al.  Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study , 2014, The Lancet.

[16]  M. Stoler,et al.  The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. , 2014, Journal of Clinical Virology.

[17]  N. Muñoz,et al.  Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. , 2014, European journal of cancer.

[18]  M. Schiffman,et al.  A Study of Genotyping for Management of Human Papillomavirus-Positive, Cytology-Negative Cervical Screening Results , 2014, Journal of Clinical Microbiology.

[19]  Deborah Bateson,et al.  Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. , 2014, The Lancet. Infectious diseases.

[20]  J. Dodds,et al.  Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis , 2014, BMJ : British Medical Journal.

[21]  R. T. Cardoso,et al.  Guía de cribado del cáncer de cuello de útero en España, 2014 , 2014 .

[22]  F. Bray,et al.  50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence , 2014, British Journal of Cancer.

[23]  K. Auranen,et al.  Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland , 2014, International journal of cancer.

[24]  E. Lazcano-Ponce,et al.  Specimen self‐collection and HPV DNA screening in a pilot study of 100,242 women , 2014, International journal of cancer.

[25]  J. Berkhof,et al.  Cervical cancer screening: on the way to a shift from cytology to full molecular screening. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  J. Cuzick,et al.  Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[27]  Thomas C Wright,et al.  Interlaboratory variation in the performance of liquid‐based cytology: Insights from the ATHENA trial , 2014, International journal of cancer.

[28]  M. Nygård,et al.  Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys , 2014, PloS one.

[29]  C. Wheeler,et al.  Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA , 2014, The Journal of infectious diseases.

[30]  J. Berkhof,et al.  Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. , 2014, The Lancet. Oncology.

[31]  S. Kjaer,et al.  Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. , 2014, Journal of the National Cancer Institute.

[32]  J. Berkhof,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[33]  P. Hillemanns,et al.  Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. , 2014, The Lancet. Oncology.

[34]  S. Franceschi,et al.  Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model , 2014, Infectious Agents and Cancer.

[35]  E. Franco,et al.  The road ahead for cervical cancer prevention and control. , 2014, Current oncology.

[36]  J. Cuzick,et al.  Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study , 2014, PLoS medicine.

[37]  M. Poljak,et al.  Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia. , 2013, Vaccine.

[38]  M. Jit,et al.  Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England☆ , 2013, Vaccine.

[39]  Y. Qiao,et al.  Lower cost strategies for triage of human papillomavirus DNA-positive women , 2013, International journal of cancer.

[40]  N. Muñoz,et al.  Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. , 2013, European journal of cancer.

[41]  S. Garland,et al.  Anal and perianal squamous carcinomas and high‐grade intraepithelial lesions exclusively associated with “low‐risk” HPV genotypes 6 and 11 , 2013, International journal of cancer.

[42]  D. Gertig,et al.  Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study , 2013, BMC Medicine.

[43]  G. Molenberghs,et al.  Model-Based Estimates of Long-Term Persistence of Induced HPV Antibodies: A Flexible Subject-Specific Approach , 2013, Journal of biopharmaceutical statistics.

[44]  S. Franceschi,et al.  Benefits of catch‐up in vaccination against human papillomavirus in medium‐ and low‐income countries , 2013, International journal of cancer.

[45]  M. Plummer,et al.  Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. , 2013, European journal of cancer.

[46]  G. Garnett,et al.  Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine , 2013, PloS one.

[47]  N. Demarteau,et al.  Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. , 2013, Vaccine.

[48]  K. Auranen,et al.  The burden and costs of prevention and management of genital disease caused by HPV in women: A population‐based registry study in Finland , 2013, International Journal of Cancer.

[49]  W. Kang,et al.  Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? , 2013, Gynecologic oncology.

[50]  D. Lowy,et al.  Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica , 2013, PloS one.

[51]  C. Wheeler,et al.  Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[52]  S. Garland,et al.  A review of clinical trials of human papillomavirus prophylactic vaccines. , 2012, Vaccine.

[53]  Jack Cuzick,et al.  New technologies and procedures for cervical cancer screening. , 2012, Vaccine.

[54]  S. Franceschi,et al.  Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries. , 2012, Vaccine.

[55]  H. Cubie,et al.  Human papillomavirus vaccine introduction--the first five years. , 2012, Vaccine.

[56]  M. Plummer,et al.  Global burden of human papillomavirus and related diseases. , 2012, Vaccine.

[57]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[58]  Peng Guan,et al.  Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer , 2012, International journal of cancer.

[59]  M. Jit,et al.  Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[60]  C. Wilkinson,et al.  Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing , 2012, British Journal of Cancer.

[61]  J. Cuzick,et al.  [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. , 2012, Epidemiologia e prevenzione.

[62]  D. Habbema,et al.  Cervical cancer screening in the United States and the Netherlands: a tale of two countries. , 2012, The Milbank quarterly.

[63]  P. Gravitt.  The known unknowns of HPV natural history. , 2011, Journal of Clinical Investigation.

[64]  J. Berkhof,et al.  The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. , 2011, Vaccine.

[65]  H. Jessen,et al.  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. , 2011, The New England journal of medicine.

[66]  M. Postma,et al.  Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. , 2011, The Journal of infectious diseases.

[67]  Jasmin A. Tiro,et al.  Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. , 2011, Vaccine.

[68]  J. Ordi,et al.  Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. , 2011, Gynecologic oncology.

[69]  N. Muñoz,et al.  End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age , 2011, British Journal of Cancer.

[70]  H. Ngan,et al.  Psychological burden of testing positive for high‐risk human papillomavirus on women with atypical cervical cytology: a prospective study , 2011, Acta obstetricia et gynecologica Scandinavica.

[71]  H. Jessen,et al.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.

[72]  L. Bruni,et al.  Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. , 2010, The Journal of infectious diseases.

[73]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[74]  J. H. van de Wijgert,et al.  Factors affecting transmission of mucosal human papillomavirus. , 2010, The Lancet. Infectious diseases.

[75]  J. Fielding,et al.  Human papillomavirus vaccine among adult women: disparities in awareness and acceptance. , 2010, American journal of preventive medicine.

[76]  B. Detournay,et al.  A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer , 2010, International Journal of Public Health.

[77]  E. Lazcano-Ponce,et al.  Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América Latina , 2010 .

[78]  S. Wacholder,et al.  Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. , 2010, Journal of the National Cancer Institute.

[79]  H. Trottier,et al.  Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. , 2010, Cancer research.

[80]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[81]  T. Iftner,et al.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.

[82]  M. Jepsen,et al.  Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark , 2010, International Journal of Technology Assessment in Health Care.

[83]  Diane Solomon,et al.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.

[84]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[85]  E. Dasbach,et al.  The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary , 2010, Journal of medical economics.

[86]  A. Anttila,et al.  Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. , 2009, Journal of the National Cancer Institute.

[87]  Marie-Pierre David,et al.  Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. , 2009, Gynecologic oncology.

[88]  S. Goldie,et al.  Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States , 2009, Annals of Internal Medicine.

[89]  E. Franco,et al.  The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. , 2009, Archives of medical research.

[90]  K. Lakshmaiah,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[91]  E. Dasbach,et al.  Age-based programs for vaccination against HPV. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[92]  Henry C Kitchener,et al.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. , 2009, The Lancet. Oncology.

[93]  N. Muñoz,et al.  Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009, The Lancet.

[94]  M. Barry,et al.  Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. , 2008, Vaccine.

[95]  S. Rosso,et al.  Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. , 2008, The Lancet. Oncology.

[96]  E. Dasbach,et al.  Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model , 2008, Expert review of pharmacoeconomics & outcomes research.

[97]  W. Prendiville,et al.  Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis , 2008, BMJ : British Medical Journal.

[98]  S. Goldie,et al.  Health and economic implications of HPV vaccination in the United States. , 2008, The New England journal of medicine.

[99]  Marc Brisson,et al.  Modeling cervical cancer prevention in developed countries. , 2008, Vaccine.

[100]  Mark Jit,et al.  Economic evaluation of human papillomavirus vaccination in the United Kingdom , 2008, BMJ : British Medical Journal.

[101]  EJ Dasbach,et al.  The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK , 2008, BJOG: an International Journal of Obstetrics and Gynaecology.

[102]  J. Cuzick,et al.  Long‐term follow‐up of cervical abnormalities among women screened by HPV testing and cytology—Results from the Hammersmith study , 2008, International Journal of Cancer.

[103]  Charlotte Paul,et al.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.

[104]  J. Dillner,et al.  Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer , 2008 .

[105]  D. Lowy,et al.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.

[106]  P. Baghurst,et al.  A cross‐sectional survey to assess community attitudes to introduction of Human Papillomavirus vaccine , 2007, Australian and New Zealand journal of public health.

[107]  P. Sparén,et al.  Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. , 2007, The Lancet. Oncology.

[108]  W. Prendiville,et al.  The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. , 2006, Cancer treatment reviews.

[109]  J. Wardle,et al.  Chapter 10: New dimensions in cervical cancer screening. , 2006, Vaccine.

[110]  F. Bray,et al.  Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.

[111]  J. Cuzick,et al.  Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. , 2006, Vaccine.

[112]  J. Wardle,et al.  Social and psychological impact of HPV testing in cervical screening: a qualitative study , 2006, Sexually Transmitted Infections.

[113]  W. Prendiville,et al.  Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis , 2006, The Lancet.

[114]  A. Trevisan,et al.  Prevalence of childhood exanthematic disease antibodies in paramedical students: need of vaccination. , 2006, Vaccine.

[115]  A. Osterhaus,et al.  Purification of phocid herpesvirus type 1 glycoproteins B and D and pilot studies of immunogenicity in mice. , 2006, Vaccine.

[116]  Thomas C Wright,et al.  Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. , 2005, JAMA.

[117]  E. Lazcano-Ponce,et al.  Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development. , 2003, Salud publica de Mexico.

[118]  P. Fuchs,et al.  Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. , 2001, The New England journal of medicine.

[119]  J. Cuzick,et al.  Human papillomavirus testing in primary cervical screening , 1995, The Lancet.

[120]  W KOUWENAAR,et al.  [The National Institute of Public Health]. , 1952, Nederlands tijdschrift voor geneeskunde.

[121]  M. Lehtinen,et al.  Clinical trials of human papillomavirus vaccines and beyond , 2015, Nature Reviews Clinical Oncology.

[122]  T. Wright,et al.  Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population. , 2015, American journal of clinical pathology.

[123]  M. Poljak,et al.  Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide , 2015, International journal of cancer.

[124]  Releve Epidemiologique Hebdomadaire.  Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations. , 2015, Vaccine.

[125]  S. Garland.  The Australian experience with the human papillomavirus vaccine. , 2014, Clinical Therapeutics.

[126]  J. R. Costa,et al.  Guideline for cervical cancer screening in Spain, 2014 , 2014 .

[127]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[128]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[129]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[130]  C. Wheeler,et al.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[131]  G. Sánchez,et al.  [New paradigms and challenges in cervical cancer prevention and control in Latin America]. , 2010, Salud publica de Mexico.

[132]  Who,et al.  Human papillomavirus vaccines: WHO position paper. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[133]  N. Muñoz.  The epidemiology of cervical cancer and humen papillomavirus , 1992 .

[134]  J. Higginson.  International Agency for Research on Cancer. , 1968, WHO chronicle.

[135]  P. Gravitt.  Send Orders of Reprints at Bspsaif@emirates.net.ae Evidence and Impact of Human Papillomavirus Latency , 2022 .